Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million
23/09/2025 06:01
Sep 23 (Reuters) - Santhera Pharmaceuticals H1 EPS CHF -3.04. H1 net income CHF -38.832 million H1 operating expenses CHF -27.334 million
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million